Electronic Acknowledgement Receipt				
EFS ID:	7218395			
Application Number:	09776936			
International Application Number:				
Confirmation Number:	8682			
Title of Invention:	INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS			
First Named Inventor/Applicant Name:	Scott Miller			
Correspondence Address:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  Arlington Courthouse Plaza I  Suite 1400  2200 Clarendon Boulevard  Arlington VA 22201  US 7032436333			
Filer:	Csaba Henter/Ashley Weber			
Filer Authorized By:	Csaba Henter			
Attorney Docket Number:	BAYER 6 P1			
Receipt Date:	16-MAR-2010			
Filing Date:	22-DEC-1998			
Time Stamp:	17:27:17			
Application Type:	Utility under 35 USC 111(a)			
Payment information:				

## **Payment information:**

Submitted with Payment	no
File Listing:	

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	DE3529247.pdf	1704794	no	79
·		2 2 3 2 1 7 1 ps.	129d9dfea6b07c6dc33d1d83c17fb0e4eb9 481dc		,,,
Warnings:					
Information:					
2	Foreign Reference	wo90002112.pdf	3129308	no	86
	J	'	22a52b0a51a9e091a5a116b62a238ce1dfef ba47		
Warnings:					
Information:					
3	Foreign Reference	wo97009973.pdf	10741786	no	318
_		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	f33b5f98d83ff8d00a7be00cc6bc06254288 c65c		
Warnings:					
Information:					
4	Foreign Reference	wo98020868.pdf	1853580	no	34
	wo30020000.pdi	895525b7f10e9e061a15581ebcd23df022b 78758	110	54	
Warnings:					
Information:					
5	Foreign Reference	wo98045268.pdf	7723932	no	200
,	roleigh Kelelence		527d2e3b5d89e2dd22742ef57c1f3254363 24efe		200
Warnings:			·	•	
Information:					
	Causing Defende	00020205 46	6416654	no	161
6	Foreign Reference	wo99028305.pdf	901989445d31e040cfe4c444919bc91f7240 9856		161
Warnings:			'	'	
Information:					
-	5	00012255	8008880	no	200
7	Foreign Reference	wo00043366.pdf	711871c09a6232347d56308b73735f807ea afc63		208
Warnings:	·		1		
Information:					
	5 : 2 (	00055224	3362651		
8	Foreign Reference	wo00056331.pdf	4b2874fd7a867bf61f629de95bfe7dc64378 a78b	- no	89
Warnings:		<u> </u>	ı	l	
Information:					
	5 1 5 1		1459197	no c	
9	Foreign Reference	wo02014331.pdf	83086daf82bc6e100bac45fc1bdd6ef380dc 6f97		38
			1		

Warnings:					
Information:					
10	Foreign Reference	WO020627630.pdf	5208168	no	125
			da6e7b0fbc0a6c53da30a0d04e05d691097 ddeab		
Warnings:					
Information:					
11	Foreign Reference	WO02083628.pdf	5772871	no	155
			b63b865dd0469a30bd16114a91207a9fa4c 0d9a8		
Warnings:					
Information:					
12	Foreign Reference	wo02085857.pdf	2888772	no	65
	j	·	a3d554e8fcba0e60947316f68e4d21ed76d d8db9		
Warnings:					
Information:					
13	Foreign Reference	wo02085859.pdf	4355339	no	97
	_	·	730c606c132b3a47801571eeb592c60ea98 0eed1		,
Warnings:					
Information:					
14	Foreign Reference	WO02092576.pdf	2861903	no	67
	_		dbf0677417074fa30a5536715d8ae76327e 1113b		
Warnings:					
Information:					
15	Foreign Reference	EP0690344.pdf	1542518	no	55
			a4308c06b6fcfdae72967d35dbd0b06a855 055cb		
Warnings:					
Information:					
16	NPL Documents	Adjei APhasel Study of BAY 43900 6 and Gefitini bin Patients with a R	69532	no	1
		efractory.pdf	a7968799ac7dd7b573f8f5ef74bd8037e219 ef4a		
Warnings:		'			
Information:					
		Ahmad Kinase Inhibition with BA	590309		
17	NPL Documents	Y439006inRenalCellCarcinoma	de2ea12045e15fc558c233d5c35aaf18d825 0810	no	5
Warnings:		1	ı		<u> </u>
Information:					
18	NPL Documents	AUCLAIRETAL.pdf	59931	no	1
10	ivi e pocuments	//oce/meral.pui	57ec9e3fecaf69331d098cf04f3bf297a40d2 c6c	110	1

Information:					
19	NPL Documents	BANKSTONDETAL.pdf	365909	no	5
			be97be697a5dfac647f08c2694be8113da7 8d958		
Warnings:					
Information:					
20	NPL Documents	Blancop38MAPKSignallingCasc adesAncientRolesandNewFunc	212665	no	9
		tions.pdf	9b6d919dbea7158136b66ceac569b372bb c71781		
Warnings:					
Information:					
21	NPL Documents	BOLLAGETALRAFPATHWAY.pdf	580972	no	6
		4fb4c	4fb4c66e936cecbd47f2644831fce04d618f 2f45		
Warnings:				'	
Information:					
22	NPL Documents	CAMPBELLETAL.pdf	2424350	no	19
	, u z z seamenta		a9005795d543aa40f07cec14e63d4b28e97 1cd17	0	
Warnings:					
Information:					
23	NPL Documents	Carter Antitum or Efficacy of the Orally Active RAFK in a seln hibitor.	201656	no	2
			a9e31c2fc690315dceb94b8cd330fb5c95f2 9181		
Warnings:					
Information:					
24	NPL Documents	Chang BAY 43-9006 Sorafenib Inhibits Ectopic SC and Orthotopic Gr	73262	no	1
		owthofaMurine.pdf	b459963e6d62393827dc61063921213bbd 2088f2		
Warnings:		·	•		
Information:					
25	NPL Documents	ClarkSafetyandPharmacokineti csoftheDualActionRafKinasean	1034920	no	9
23	Nr L Documents	d.pdf	c2eaf2ee4a6b212855a63595dc5c705ba2d 4a2a1	110	9
Warnings:		· · ·			
Information:					
		Danson Improving Outcomes in	859338		
26	26 NPL Documents	AdvancedMalignantMelanoma.	9cc2dcc7f02852a3f5f9fd111ffd4812a16509	no	11
Warnings:			3a		
Information:					
27	NPL Documents	DeGrendele Activity of the Raf Kin as eInhibitor BAY43-900 6 in Patie	222928		-
//	NEL DOCUMENTS	ntswithAdvancedSolidTumors.		no	3

Warnings:					
Information:					
28	NPL Documents	Dumas Protien Kinase Inhibitors f	750454	no	10
		orm the Urea Class.pdf	2832fb0f9b242eda77836f4466046fb88d49 bb03		
Warnings:					
Information:					
29	NPL Documents	DUMASETALRECENTDEVELOP	1504470	no	17
		MENTS.pdf	a7efd78f85b6b6ef445dc8515c2cc0a9e2b6 3467		
Warnings:					
Information:					
30	NPL Documents	DUMASJETALSYNTHESISANDP	383855	no	4
		HARMACOLO.pdf	2b8f8b9166e7979db25a7ead1bfc56bc83f8 824e		
Warnings:					
Information:					
31	NPL Documents	DumasETALDISCOVERYOFACL	293780	no	4
		ASSOFP38KINASE.pdf	06d6b261074838c75fc308b0982ec344d69 853d9		
Warnings:					
Information:					
32	NPL Documents	Eisen Phasel Trial of BAY43-9006S or a fenib Combined with Dacarb azine DTI Cin Metastatic Melano	66103	no	1
		maPatients.pdf	3a7f066aab69cb172c667761be6e3477f0a3 857d		
Warnings:					
Information:					
33	NPL Documents	Eisenhauer Impact of New Non- Cytotoxics in the Treatment of Ov	512335	no	5
		arianCancer.pdf			
Warnings:					
Information:					
34	NPL Documents	Escudier Randomized Phase III Tri al of the Raf Kinaseand VEGFRInhi	71404	no	1
	, we became me	bitorSorafenib.pdf	753890aeb5577b3cfc9c9bf5940b45db5d1 30347	0	·
Warnings:		'			
Information:					
			662046		
35	NPL Documents	FactsandComparisons1994editi on.pdf	7becd3b04c38301d229988d589cc253a62f e132e	no	4
Warnings:			CIDEC		<u> </u>
Information:					
36	NPL Documents	Garcia- Lopez New Routes for the Synthes	370184	no	5
55	W E Documents	isofPyrrolo.pdf	c3a552d6f36f031d0e512d7a5ef3945617f3 c8f1	110	

Warnings:					
Information:					
37	NPL Documents	Hanson Inhibitors of p38 Kinase In genta Connect Inhibitors of p38 Ki nase.pdf		no	1
		nase.pui	97525cc9697036487c5b3927df8fcf89fcd30 ded		
Warnings:					
Information:					
38	NPL Documents	HeimAntitumorEffectandPoten tiationorReductioninCytotoxic	157173	no	2
		Drug Activity in Human Colon.pdf	7169f3e4d1dc69a36e024144c1488a619d0 6ec8a		
Warnings:					
Information:					
39	NPL Documents	HOTTEETAL.pdf	393065	no	5
39	NEL Documents	HOTTEETAL.pui	bd39dfa317300b5af30df69f1dae4abbabe9 37a2	no	3
Warnings:					
Information:					
40	NPL Documents	Hubbard Oncogenic Mutationsi nB-Raf Some Losses Yield Gains.	318340		,
40	NPL Documents	pdf	aa4606bf21651dd0f853acd9f86cb27ad593 323c	no	3
Warnings:					
Information:					
41	NPL Documents	KEMPTERETAL.pdf	1396625	no	20
41	Nr E Documents		863d918d661894f9b291f00469c99627d67f 30f4		
Warnings:					
Information:					
42	NPL Documents	KHIREETAL.pdf	262018	no	4
			408ca3abac2119211e21d1a9488992b06bc cc4db		·
Warnings:					
Information:					
43	NPL Documents	LEFETAL - df	589793		7
45	NEL Documents	LEEETAL.pdf	79315a4885e24a64b95e2814280cb76f497 a2eb8	no	7
Warnings:					
Information:					
		LOW/DINICEDETAL DICCOVEDOSC	627223	no	
44	44 NPL Documents	LOWRINGERETALDISCOVEROFS MALLMOLECULES.pdf	8e6d002b01e201bc26cd7a46bdc927b8b8 901dad		10
Warnings:		1			I
Information:					
45	NPL Documents	Lowingeretal Protein Kinaselnhi	148446	no	1
.5	= = = = = = = = = = = = = = = = = =	bitors From The Urea Class.pdf	30e948a99d7bb5597bb1f19ad97857c84f9 3816c		

Warnings:					
Information:					
46	NPL Documents	LYONSETAL.pdf	816218	no	8
		· ·	8eea8beb1e240da3dce3c172182060977aa 09dd3		
Warnings:					
Information:					
47	NPL Documents	MadwedPharmacologicalEvalu	77971	no	1
		ation of BIRB 796.pdf	3c344521d14e8c7195376b0585cdda35d36 b3827		
Warnings:					
Information:					
48	48 NPL Documents	MOELLINGETAL.pdf	845713	no	9
			d854d5f274e66f19e2dee584ac485e9b3f95 8363		
Warnings:					
Information:					
49	NPL Documents	MOOREETAL.pdf	576594	no	7
		'	db64f73bec08411e7b7c8e73f962302bc13 ce4c6		,
Warnings:					
Information:					
50	NPL Documents	MROSSETAL.pdf	187834	no	2
			f064cbd2ce52755e1c37f91c8ef1e4f066ad7 aa3		
Warnings:					
Information:					
51	NPL Documents	MURPHYETAL.pdf	71331	no	1
		·	eaa09e87ae893a81e3098b874af9d0cfe6fc 0f16		
Warnings:					
Information:					
52	NPL Documents	Nickel Carboxylic Acid Analogue sof Suramin Potential Filaricides.	415868	no	6
32	THE BOCKMENTS	pdf	ed513fa9a0683d837c8fddaa3a273a0f030d b344	110	6
Warnings:		1			
Information:					
			43543		
53	NPL Documents	Panka BAY43-9006 Induces Apop to sis in Melanoma Cell Lines. pdf	a9f5edfa6b063c3061ffdff88b7249a3898d9 09c	no	1
Warnings:		I			l
Information:					
54	NPL Documents	WilhelmANovelDiphenylureaRa fKinaseInhibitorRKIBlockstheRa	52216	no	1
		fMEKERKPathwayinTumorCells. pdf	7c0cbd73df9ee2931c101c9d5ab256d20b7 897db		'

Warnings:					
Information:					
55	NPL Documents	REDMANETAL.pdf	293632	no	4
			a848fd4b8500125737a303d06155678ed22 cbf03		
Warnings:			1		
Information:					
56	NPL Documents	ReganPyrazoleUrea- BasedInhibitorsofp38MAPKinas	1709151	no	15
		eFormLeadCompoundtoClinica lCandidate.pdf	bd0f3cf673fd0f61918fa7233d3f914b02b1b 853		
Warnings:		·	<u> </u>		
Information:					
57	NPL Documents	RichlyAPhaselClinicalandPharm acokineticStudyoftheRafKinasel	243578	no	2
		nhibitorRKIBAY43-9006.pdf	9818659724aff1c539a56ef398c94ae49f72a 023		
Warnings:			·		
Information:					
58	NPL Documents	RichlyResultsofaPhaselTrialofB AY43-9006inCombinationwith Doxorubicinin.pdf	139610	no	2
			2fec20c5fbf1be3b15266221b98a57f7649fd 011		
Warnings:		·	•		
Information:					
59	NPL Documents	RiedletalPotentRafKinaseInhibit	43951	no	1
		ors from the Diphenyl.pdf	5482a07d7acbf10d71951c23c8902ee4b53 4f5d2		
Warnings:			·		
Information:					
60	NPL Documents	SiuPhaselStudyofOralRaf1Kinas	63765	no	1
	500	elnhibitor.pdf	1c1e419fb190b49ffb58da67140cea5d5008 c995		•
Warnings:			•		
Information:					
		Total Files Size (in bytes)	8786	4277	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

## New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

## National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

## New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.